GL-2045 Stradomer Manufacturing for Consistent Multimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing manufacturing methods for GL-2045 result in varying levels of cell viability, protein titer, and multimerization, leading to inconsistent efficacy in treating autoimmune and inflammatory diseases.
Innovation Solution
Optimized upstream and downstream manufacturing processes, including specific culture conditions and purification techniques, to achieve high cell viability, protein titer, and defined multimer patterns of GL-2045, enhancing its therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard manufacturing methods are used for GL-2045, then production can be maintained with conventional processes, but cell viability varies, protein titer is inconsistent, and multimerization levels are unpredictable leading to variable therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by systematically optimizing culture conditions including temperature shifts (37°C to 32°C), pH control (7.0 to 7.4), dissolved oxygen levels (40-60%), and feed supplementation schedules. These parameter modifications consistently achieve >90% cell viability, >10 g/L protein titer, and controlled multimerization patterns, resolving the inconsistency in therapeutic efficacy while maintaining manageable manufacturing complexity through defined process parameters
2Manufacturing precision
If manufacturing conditions are optimized to achieve high cell viability and protein titer, then therapeutic efficacy improves, but the manufacturing process becomes more complex and difficult to control
Solution Approach 1:
The patent implements preliminary action by pre-defining optimal culture conditions and feed supplementation schedules before production begins. The process establishes target parameters in advance (temperature shift timing, pH setpoints, dissolved oxygen levels) that guide manufacturing operations, enabling precise multimerization control without requiring complex real-time adjustments during production
Solution Approach 2:
The patent employs feedback mechanisms through monitoring cell viability, protein titer, and multimerization patterns throughout the manufacturing process. This allows real-time assessment of process performance and adjustment of culture conditions to maintain optimal parameters, achieving consistent manufacturing precision while managing process control complexity through data-driven decisions
Data Source
AI summary
The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.